A field trial with an experimental vaccine against Staphylococcus aureus mastitis in cattle. 1. Clinical parameters.
A total of 108 heifers were included in a placebo-controlled multicenter study on the use of an experimental Staphylococcus aureus mastitis vaccine containing whole, inactivated bacteria with pseudocapsule, alpha and beta toxoids, and a mineral oil as adjuvant. The heifers were injected in the area of the supramammary lymph nodes twice before calving and were observed and sampled throughout the first lactation. None of the vaccinated cows suffered from clinical Staph. aureus mastitis, and only 8.6% suffered from subclinical Staph. aureus mastitis, but a total of 16.0% of the control cows suffered from clinical or subclinical Staph. aureus mastitis. Mean SCC in vaccinated and control cows were the same throughout the lactation. Local swellings at the injection site were palpable in a substantial proportion of the vaccinated cows. In the statistical analyses, when cow was used as the unit of concern, no significant differences occurred between groups. However, when all parameters on udder health were considered together, the results indicated a potential protective effect of this vaccine during the entire lactation.
Nordhaug
M L
ML
Department of Immunoprophylaxis, Central Veterinary Laboratory, Oslo, Norway.
Nesse
L L
LL
Norcross
N L
NL
Gudding
R
R
D000818:Animals; D002417:Cattle; D005260:Female; D007774:Lactation; D008414:Mastitis, Bovine / Q000517:prevention & control*; D013209:Staphylococcal Vaccines / Q000009:adverse effects; D013211:Staphylococcus aureus / Q000276:immunology*
D013209:Staphylococcal Vaccines